Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:303–312

Article  CAS  PubMed  Google Scholar 

Yoshino T, Komatsu Y, Yamada Y, Yamazaki K, Tsuji A, Ura T et al (2015) Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations. Invest New Drugs 33:740–750

Article  CAS  PubMed  Google Scholar 

Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G et al (2017) Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389:56–66

Article  CAS  PubMed  Google Scholar 

Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H et al (2013) Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:295–302

Article  CAS  PubMed  Google Scholar 

Saito Y, Takekuma Y, Komatsu Y, Sugawara M (2024) Impact of preexisting proteinuria on the development of regorafenib-induced problematic proteinuria in real-world metastatic colorectal cancer treatment. Sci Rep 14:5153

Article  CAS  PubMed  PubMed Central  Google Scholar 

Saito Y, Takekuma Y, Komatsu Y, Sugawara M (2023) Severe hypertension development significantly improves progression-free survival in regorafenib treatment for metastatic colorectal cancer. Int J Clin Oncol 28:1183–1190

Article  CAS  PubMed  Google Scholar 

Kanbayashi Y, Ishikawa T, Tabuchi Y, Sakaguchi K, Ouchi Y, Otsuji E et al (2020) Predictive factors for the development of proteinuria in cancer patients treated with bevacizumab, ramucirumab, and aflibercept: a single-institution retrospective analysis. Sci Rep 10:2011

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nihei S, Sato J, Harada T, Kuyama S, Suzuki T, Waga N et al (2018) Antiproteinuric effects of renin-angiotensin inhibitors in lung cancer patients receiving bevacizumab. Cancer Chemother Pharmacol 81:1051–1059

Article  CAS  PubMed  Google Scholar 

Bekaii-Saab TS, Ou FS, Ahn DH, Boland PM, Ciombor KK, Heying EN et al (2019) Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. Lancet Oncol 20:1070–1082

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stivarga tablets® [package insert on the internet]. Bayer Yakuhin., 2019. https://pharma-navi.bayer.jp/sites/g/files/vrxlpx9646/files/2020-11/STI_MPI_201909240_1568962296.pdf. Accessed Apr 19, 2024

Ikesue H, Yamamoto H, Hirabatake M, Hashida T, Chung H, Inokuma T et al (2022) Risk factors of proteinuria in patients with hepatocellular carcinoma receiving lenvatinib. Biol Pharm Bull 45:333–338

Article  CAS  PubMed  Google Scholar 

Ikesue H, Yamaoka K, Matsumoto A, Hirabatake M, Muroi N, Yamasaki T et al (2022) Risk factors of proteinuria and potentially protective effect of renin-angiotensin system inhibitors in patients with renal cell carcinoma receiving axitinib. Cancer Chemother Pharmacol 89:833–838

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nakamura K, Tanaka T, Masumori N, Miyamoto A, Hirano T (2020) Evaluation of proteinuria using urine protein : creatine ratio in treatment with molecular targeted agents for advanced renal cell carcinoma. Biol Pharm Bull 43:1506–1510

Article  CAS  PubMed  Google Scholar 

Ando Y, Nishiyama H, Shimodaira H, Takano N, Sakaida E, Matsumoto K et al. (2023) Chapter 3: Management of kidney injury caused by cancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022. Int J Clin Oncol 28:1315-1332

Yamaguchi K, Komatsu Y, Satoh T, Uetake H, Yoshino T, Nishida T et al (2019) Large-scale, prospective observational study of regorafenib in Japanese patients with metastatic colorectal cancer in a real-world clinical setting. Oncologist 24:e450–e457

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nihei S, Asaka J, Takahashi H, Kudo K (2021) Bevacizumab increases endothelin-1 production via forkhead box protein O1 in human glomerular microvascular endothelial cells in vitro. Int J Nephrol 2021:8381115

Article  PubMed  PubMed Central  Google Scholar 

Person F, Rinschen MM, Brix SR, Wulf S, Noriega MLM, Fehrle W et al (2019) Bevacizumab-associated glomerular microangiopathy. Mod Pathol 32:684–700

Article  CAS  PubMed  Google Scholar 

Ollero M, Sahali D (2015) Inhibition of the VEGF signalling pathway and glomerular disorders. Nephrol Dial Transplant 30:1449–1455

Article  CAS  PubMed  Google Scholar 

Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J et al (2008) VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 358:1129–1136

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sison K, Eremina V, Baelde H, Min W, Hirashima M, Fantus IG et al (2010) Glomerular structure and function require paracrine, not autocrine, VEGF-VEGFR-2 signaling. J Am Soc Nephrol 21:1691–1701

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kobayashi K, Kawakami K, Yokokawa T, Aoyama T, Suzuki K, Wakatsuki T et al (2019) Association of hand-foot skin reaction with regorafenib efficacy in the treatment of metastatic colorectal cancer. Oncology 96:200–206

Article  CAS  PubMed  Google Scholar 

McLellan B, Ciardiello F, Lacouture ME, Segaert S, Van Cutsem E (2015) Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management. Ann Oncol 26:2017–2026

Article  CAS  PubMed  PubMed Central  Google Scholar 

Katakami N, Uchino J, Yokoyama T, Naito T, Kondo M, Yamada K et al (2018) Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04). Cancer 124:606–616

Article  CAS  PubMed  Google Scholar 

Saito Y, Takekuma Y, Komatsu Y, Sugawara M (2022) Risk factor analysis for regorafenib-induced severe hypertension in metastatic colorectal cancer treatment. Support Care Cancer 30:10203–10211

Article  PubMed  Google Scholar 

Kobayashi K, Sugiyama E, Shinozaki E, Wakatsuki T, Tajima M, Kidokoro H et al (2021) Associations among plasma concentrations of regorafenib and its metabolites, adverse events, and ABCG2 polymorphisms in patients with metastatic colorectal cancers. Cancer Chemother Pharmacol 87:767–777

Article  CAS  PubMed  Google Scholar